A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients

Miroslava Bosheva, Rusudan Gujabidze, Éva Károly, Agnes Nemeth, Mikael Saulay, Jennifer I Smart, Kamal A Hamed, Miroslava Bosheva, Rusudan Gujabidze, Éva Károly, Agnes Nemeth, Mikael Saulay, Jennifer I Smart, Kamal A Hamed

Abstract

Background: The advanced-generation, broad-spectrum, intravenous (IV) cephalosporin, ceftobiprole, is an effective and well-tolerated treatment for adults with hospital-acquired pneumonia (HAP) or community-acquired pneumonia (CAP), but its effects in pediatric patients have not been established.

Methods: In this multicenter, investigator-blinded, active-controlled, phase 3 study, patients 3 months to <18 years old with HAP or CAP requiring hospitalization were randomized (2:1) to ceftobiprole versus standard-of-care (SoC) IV cephalosporin treatments (ceftazidime or ceftriaxone), with or without vancomycin. After at least 3 days' IV treatment, patients demonstrating clinical improvement could be switched to an oral antibiotic, to complete a minimum of 7 days' treatment.

Results: Overall, 138 patients were randomized to ceftobiprole (n = 94) or a SoC cephalosporin (n = 44). Median time to oral switch was 6.0 days in the ceftobiprole group and 8.0 days in the SoC cephalosporin group. While on IV therapy, adverse events and treatment-related adverse events were reported by 20.2% and 8.5% of ceftobiprole-treated patients and 18.2% and 0% of SoC cephalosporin-treated patients. Early clinical response rates at day 4 in the intention-to-treat population were 95.7% and 93.2% (between-group difference, 2.6%; 95% confidence interval, -5.5% to 14.7%) in the ceftobiprole and comparator groups, and clinical cure rates at the test-of-cure visit were 90.4% and 97.7% (between-group difference, -7.3%; 95% confidence interval, -15.7% to 3.6%), respectively.

Conclusions: Ceftobiprole was well tolerated and, in this small phase 3 study, demonstrated similar efficacy to SoC cephalosporins in pediatric patients with HAP or CAP requiring hospitalization.

Trial registration: ClinicalTrials.gov NCT03439124.

Conflict of interest statement

M.S., J.I.S. and K.A.H. are employees of Basilea Pharmaceutica International Ltd. The other authors have no conflicts of interest to disclose.

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

Figures

FIGURE 1.
FIGURE 1.
Consort flow diagram for trial screening and randomization.
FIGURE 2.
FIGURE 2.
Kaplan-Meier curve of the time to switch to oral antibiotic in the intent-to-treat population.
FIGURE 3.
FIGURE 3.
Early clinical response and clinical cure rates on day 4 and at the end-of-treatment, test-of-cure and last follow-up visits in the intent-to-treat and clinically evaluable populations. Early clinical response was assessed at day 4 and clinical cure at end-of-treatment, test-of-cure and last follow-up visits. CE indicates clinically evaluable.

References

    1. Liu L, Oza S, Hogan D, et al. . Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015;385:430–440.
    1. McAllister DA, Liu L, Shi T, et al. . Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysis. Lancet Glob Health. 2019;7:e47–e57.
    1. Madhi SA, De Wals P, Grijalva CG, et al. . The burden of childhood pneumonia in the developed world: a review of the literature. Pediatr Infect Dis J. 2013;32:e119–e127.
    1. Harris M, Clark J, Coote N, et al. . British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011;66(suppl 2):ii1.
    1. Rudan I, O’Brien KL, Nair H, et al. ; Child Health Epidemiology Reference Group (CHERG). Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health. 2013;3:010401.
    1. McCracken GH., Jr. Diagnosis and management of pneumonia in children. Pediatr Infect Dis J. 2000;19:924–928.
    1. Mathur S, Fuchs A, Bielicki J, et al. . Antibiotic use for community-acquired pneumonia in neonates and children: WHO evidence review. Paediatr Int Child Health. 2018;38sup1S66–S75.
    1. Carrillo-Marquez MA, Hulten KG, Hammerman W, et al. . Staphylococcus aureus pneumonia in children in the era of community-acquired methicillin-resistance at Texas Children’s Hospital. Pediatr Infect Dis J. 2011;30:545–550.
    1. Richards MJ, Edwards JR, Culver DH, et al. . Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Pediatrics. 1999;103:e39.
    1. Raymond J, Aujard Y. Nosocomial infections in pediatric patients: a European, multicenter prospective study. European Study Group. Infect Control Hosp Epidemiol. 2000;21:260–263.
    1. Chomton M, Brossier D, Sauthier M, et al. . Ventilator-associated pneumonia and events in pediatric intensive care: a single center study. Pediatr Crit Care Med. 2018;19:1106–1113.
    1. Srinivasan R, Asselin J, Gildengorin G, et al. . A prospective study of ventilator-associated pneumonia in children. Pediatrics. 2009;123:1108–1115.
    1. El-Nawawy A, Ramadan MA, Antonios MA, et al. . Bacteriologic profile and susceptibility pattern of mechanically ventilated paediatric patients with pneumonia. J Glob Antimicrob Resist. 2019;18:88–94.
    1. Mansour MGE, Bendary S. Hospital-acquired pneumonia in critically ill children: incidence, risk factors, outcome and diagnosis with insight on the novel diagnostic technique of multiplex polymerase chain reaction. Egyptian J Med Hum Genet. 2012;13:99–105.
    1. Liapikou A, Cillóniz C, Torres A. Ceftobiprole for the treatment of pneumonia: a European perspective. Drug Des Devel Ther. 2015;9:4565–4572.
    1. Morosini MI, Díez-Aguilar M, Cantón R. Mechanisms of action and antimicrobial activity of ceftobiprole. Rev Esp Quimioter. 2019;32(suppl 3):3–10.
    1. Electronic Medicines Compendium. Zevtera 500 mg powder for concentrate for solution for infusion. 2018. Available at: . Accessed January 4, 2021.
    1. Awad SS, Rodriguez AH, Chuang YC, et al. . A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014;59:51–61.
    1. Nicholson SC, Welte T, File TM, Jr, et al. . A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012;39:240–246.
    1. Overcash J, Kim C, Keech R, et al. . Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: results of a phase 3, randomized, double-blind trial (TARGET) [published online ahead of print September 8, 2020]. Clin Infect Dis. doi: 10.1093/cid/ciaa974.
    1. Torres A, Mouton JW, Pea F. Pharmacokinetics and dosing of ceftobiprole medocaril for the treatment of hospital- and community-acquired pneumonia in different patient populations. Clin Pharmacokinet. 2016;55:1507–1520.
    1. Cannavino CR, Nemeth A, Korczowski B, et al. . A randomized, prospective study of pediatric patients with community-acquired pneumonia treated with ceftaroline versus ceftriaxone. Pediatr Infect Dis J. 2016;35:752–759.
    1. Blumer JL, Ghonghadze T, Cannavino C, et al. . A multicenter, randomized, observer-blinded, active-controlled study evaluating the safety and effectiveness of ceftaroline compared with ceftriaxone plus vancomycin in pediatric patients with complicated community-acquired bacterial pneumonia. Pediatr Infect Dis J. 2016;35:760–766.
    1. Bradley JS, Arrieta A. Empiric use of cefepime in the treatment of lower respiratory tract infections in children. Pediatr Infect Dis J. 2001;20:343–349.
    1. Schuler D. Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. J Antimicrob Chemother. 1995;36(suppl A):99–108.
    1. Talbot GH, Powers JH, Fleming TR, et al. ; CABP-ABSSSI Project Team. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin Infect Dis. 2012;55:1114–1121.
    1. Food and Drug Administration. Guidance for industry: Community acquired bacterial pneumonia - developing drugs for treatment. 2014. Available at: . Accessed January 4, 2021.
    1. Bart SM, Nambiar S, Gopinath R, et al. . Concordance of early and late endpoints for community-acquired bacterial pneumonia trials [published online ahead of print June 25, 2020]. Clin Infect Dis. doi: 10.1093/cid/ciaa860.
    1. Talbot GH, Powers JH, Hoffmann SCBiomarkers Consortium of the Foundation for the National Institutes of Health CABP-ABSSSI and HABP-VABP Project Teams. Developing outcomes assessments as endpoints for registrational clinical trials of antibacterial drugs: 2015 update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin Infect Dis. 2016;62:603–607.
    1. Kaplan SL, Deville JG, Yogev R, et al. ; Linezolid Pediatric Study Group. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J. 2003;22:677–686.
    1. Jantausch BA, Deville J, Adler S, et al. . Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant Gram-positive bacterial pathogens. Pediatr Infect Dis J. 2003;22(9 suppl):S164–S171.
    1. Berman SJ, Fogarty CM, Fabian T, et al. ; Merrem Hospital-Acquired Pneumonia Study Group. Meropenem monotherapy for the treatment of hospital-acquired pneumonia: results of a multicenter trial. J Chemother. 2004;16:362–371.
    1. Rutledge-Taylor K, Matlow A, Gravel D, et al. ; Canadian Nosocomial Infection Surveillance Program. A point prevalence survey of health care-associated infections in Canadian pediatric inpatients. Am J Infect Control. 2012;40:491–496.
    1. Jacobs RF. Nosocomial pneumonia in children. Infection. 1991;19:64–72.
    1. Zar HJ, Cotton MF. Nosocomial pneumonia in pediatric patients: practical problems and rational solutions. Paediatr Drugs. 2002;4:73–83.
    1. Muller AE, Punt N, Engelhardt M, et al. . Pharmacokinetics and target attainment of ceftobiprole in Asian and non-Asian subjects. Clin Pharmacol Drug Dev. 2018;7:781–787.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren